In markets characterized by instability, defensive investment solutions are needed that are tuned for times of increased volatility by means of reduced risk.
One of the ways to mitigate the probability of a barrier event is to use "last look" BRCs. These have the characteristic that the barrier is not tested until the product expires. This means that the performance of the underlying stocks during the life of the product is irrelevant, regardless of whether they temporarily fall below the barrier. As long as all the underlying stocks are above the barrier at expiration, the investor gets back the entire capital invested - unlike with "classic" BRCs, where the barrier is continuously monitored.
Investors who expect moving markets in the coming months, but assume that the underlying assets will stabilize above the respective barrier after maturity, can benefit from attractive coupons.
Last Look CBRC auf Nestlé, Novartis, Roche, Zurich und UBS
Barriere 50% - 6.5% CouponÃÂ p.a.
Barriere 60% - 9% CouponÃÂ p.a.
Barriere 70% - 11% CouponÃÂ p.a.
18 Monate Laufzeit, Zeichnungsfrist morgen 20. Juli 2022, 16:00 Uhr
Last Look CBRC auf Holcim, Sika, Lonza und Richemont
Barriere 50% - 8.5% Coupon p.a.
Barriere 60% - 12.5% CouponÃÂ p.a.
Barriere 70% - 16% CouponÃÂ p.a.
12 Monate Laufzeit, Zeichnungsfrist morgen 20. Juli 2022, 16:00 Uhr
Last Look CBRC SMI®, Euro Stoxx 50®, S&P 500®
Barriere 60% - 4% CouponÃÂ p.a.
18 Monate Laufzeit, Zeichnungsfrist morgen 20. Juli 2022, 16:00 Uhr
Zeichnungsfrist heute, 16:00 Uhr: CBRC auf Nestlé, Novartis, Roche, Zurich und UBS
Barriere 60% - 12% Coupon p.a., reguläre Barrierebetrachtung
12 Monate Laufzeit, Zeichnungsfrist heute 19. Juli 2022, 16:00 Uhr
Alle Angaben indikativ
Disclaimer
This communication is for marketing purposes. It is neither an offer nor an invitation to submit an offer, to purchase or to subscribe to securities and does not constitute investment advice. You should consult your advisors before making an investment decision.
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, financial condition, development or performance of the issuer to be materially different from any future results, financial condition, development or performance expressed or implied by such statements.
The present document has not been drawn up by the research department as defined in the rules of the “Directives on the Independence of Financial Research” published by the Swiss Bankers Association, hence these rules do not apply to this document.
If securities are mentioned in the communication, the base prospectus, the final terms and any key information document may be obtained free of charge from Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zurich, VRIS, and from www.zkb.ch/finanzinformationen.
ZKB Barrier Reverse Convertible mit bedingtem Coupon on worst of Salesforce.com Inc/NVIDIA Corp/Supe... 132913957 / CH1329139575 |
ZKB Autocallable Barrier Reverse Convertible on worst of Biogen Inc/BioNTech SE/Moderna Inc 132913422 / CH1329134220 |
ZKB Reverse Convertible auf Moderna Inc 135805537 / CH1358055379 |
22.09% ZKB Reverse Convertible, 16.01.2025 on worst of NVDA UW/TSLA UW/MRNA UW NVIDIA Corp/Tesla Inc... 130398418 / CH1303984186 |
11.17% ZKB Reverse Convertible, 03.03.2025 on worst of QCOM UW/AAL UW/MRNA UW Qualcomm Inc/American ... 135805027 / CH1358050271 |